News - Licensing, Roche

Filter

Current filters:

LicensingRoche

Popular Filters

1 to 25 of 1292 results

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Sentinel Oncology in deal with Oncothyreon worth a potential $174 million

22-04-2014

UK-based small molecule drug discovered Sentinel Oncology has signed a collaboration agreement with the…

BiotechnologyLicensingOncologyOncothyreonResearchSentinel Oncology

Biogen Idec exercises option for Amunix’ XTENylated Factor VIII

21-04-2014

US privately-held biotech firm Amunix Operating says that Biogen Idec has exercised its option to enter…

AmunixBiogen IdecBiotechnologyHematologyLicensing

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

Dutch biotech Mucosis partners with Chinese firm

Dutch biotech Mucosis partners with Chinese firm

15-04-2014

Dutch biotech company Mucosis has entered into a long-term collaboration and license agreement with China-based…

BiotechnologyChangchunChief executiveChinaDiseaseHuman respiratory syncytial virusLicensingMimopath technologyNetherlandsVaccines

Roche starts 2014 with sales dip due to strong franc

Roche starts 2014 with sales dip due to strong franc

15-04-2014

Swiss pharma major Roche kicked of the 2014 financial results reporting season, posting a 1% dip in group…

FinancialPharmaceuticalRoche

EMA concludes inquiry into Roche infringement procedure

EMA concludes inquiry into Roche infringement procedure

14-04-2014

The European Medicines Agency says it has concluded its inquiry into alleged non-compliance with pharmacovigilance…

EuropePharmaceuticalRegulationRoche

RaQualia and Asahi Kasei Pharma progress their collaboration

RaQualia and Asahi Kasei Pharma progress their collaboration

14-04-2014

RaQualia Pharma says that its ongoing joint research with fellow Japanese drugmaker Asahi Kasei Pharma…

Asahi KaseiJapanLicensingPharmaceuticalRaQualia PharmaResearch

UAE’s Julphar inks five-year deal to market Merck & Co drugs

11-04-2014

United Arab Emirates-based drugmaker Julphar has signed a five-year licensing deal with US pharma giant…

JulpharLicensingMerck & CoPharmaceutical

Ampio’s Vyrix unit out-licenses certain rights for Zertane to Paladin

10-04-2014

USA-based biotech firm Ampio Pharmaceuticals says its wholly-owned subsidiary Vyrix Pharmaceuticals…

Ampio PharmaceuticalsBiotechnologyEndo Health SolutionsLicensingMen's HealthPaladin LabsVyrix PharmaceuticalsZertane

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

UK’s ValiRx forms joint venture to fast track lung cancer drug to Phase II

08-04-2014

UK biopharmaceutical company ValiRx has established ValiSeek, a joint venture company with Tangent Reprofiling.

Chief executiveLicensingLung cancerOncologyPharmaceuticalResearchScienceUKValiRxValiSeek

Almirall gains European rights to InDex Pharma’s Kappaproct

07-04-2014

Sweden’s InDex Pharmaceuticals and Spain’s largest drugmaker Almirall have signed a license agreement…

AlmirallEuropeGastro-intestinalsInDex PharmaceuticalsKappaproctLicensingPharmaceutical

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

1 to 25 of 1292 results

Back to top